LifeSynch Elements for Annual Performance Measures

For the Bipolar Disorder practice guidelines, LifeSynch measures performance with a) the prescription of mood-stabilizing medication and b) education of the patient or family regarding Bipolar Disorder. Both measures are based on specific recommendations in the guideline. The first is based on numerous recommendations in the CPG for first-line psychopharmacologic treatment. The second is based on recommendations about the importance of educating patients and appropriate family members.

For the Major Depressive Disorder practice guidelines, LifeSynch measures performance with a) the completion of a risk assessment and b) education of the patient or family regarding depression. Both measures are based on specific recommendations in the guideline. The first is based on a clear recommendation that an assessment of suicide risk is crucial. The second is based on a recommendation regarding the importance of educating patients and appropriate family members.

For the Substance Use practice guidelines, LifeSynch measures performance with a) the completion of an assessment for co-morbid disorders and b) referral to a support group such as AA or NA. Both measures are based on specific recommendations in the guideline. The first is based the recommendation that co-morbidity should be assessment due to the high prevalence of co-morbid psychiatric conditions in substance abuse patients. The second is based on a recommendation regarding the importance of self-help group support as active participation has been correlated with better treatment outcomes.

For the Attention-Deficit/Hyperactivity Disorder practice parameters, LifeSynch measures performance with a) the completion of an assessment for co-morbid disorders and b) referral to a support group such as Children and Adults with Attention Deficit-Hyperactivity Disorder (CHADD). Both measures are based on specific recommendations in the guideline. The first is based the recommendation that co-morbidity should be assessment due to the high prevalence of co-morbid psychiatric conditions in ADHD patients. The second is based on a recommendation regarding the importance of self-help group support.